Abstract
Brain tumors are the most common solid tumors in children and gliomas are the most common subtype. Despite their relative frequency, malignant gliomas have a 10-fold lower incidence in children compared to adults. As a result, prognostic variables in adults are extrapolated to pediatric patients for treatment decision making and patient counseling. In this review, we outline the known clinical- and treatmentrelated factors associated with outcome in pediatric high-grade glioma (HGG). We define the limitations of using adult HGG to drive pediatric HGG decision making by showing a unique molecular signature and oncogenic pathway in pediatric HGG that is distinct from adult HGG. Biologic determinants of prognosis are reviewed.
Original language | English (US) |
---|---|
Pages (from-to) | 23-29 |
Number of pages | 7 |
Journal | European journal of Clinical and Medical Oncology |
Volume | 4 |
Issue number | 3 |
State | Published - Dec 1 2012 |
Keywords
- Astrocytoma
- Biomarkers
- Glioma
- Malignant
- Pediatric
- Prognosis
ASJC Scopus subject areas
- Oncology